Tily Hajra Ismail, Perl Andras
State University of New York Upstate Medical University, Medicine/Rheumatology, 750 East Adams Street, Syracuse, New York, 13210, USA.
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.07.2008.0520. Epub 2009 Mar 5.
This report describes the development of lymphoedema in a patient with rheumatoid arthritis (RA) who was treated with tumour necrosis factor α (TNFα) inhibitors.The patient was a 62-year-old woman with a long-standing history of RA that had been uncontrolled with steroids and methotrexate. Eight months after initiation of treatment with TNFα inhibitors she developed progressive symmetrical ascending non-pitting oedema of both legs with extensive keratinisation. A diagnosis of lymphoedema was made based on the clinical presentation and exclusion of alternative diagnoses. Skin biopsy showed dermatosclerosis consistent with lymphoedema. The temporal relationship suggested a link between the initiation of TNFα inhibitors and the development of lymphoedema. TNFα inhibitors are widely used to treat inflammatory diseases including lymphoedema. Paradoxically, there are reports suggesting the appearance of psoriasis, vasculitis and other inflammatory cutaneous conditions after the use of TNFα inhibitors. A review of literature is also presented.
本报告描述了一名类风湿关节炎(RA)患者在接受肿瘤坏死因子α(TNFα)抑制剂治疗后发生淋巴水肿的情况。该患者为一名62岁女性,有长期RA病史,使用类固醇和甲氨蝶呤治疗效果不佳。在开始使用TNFα抑制剂治疗8个月后,她出现了双下肢进行性对称性上行性非凹陷性水肿,并伴有广泛的角质化。根据临床表现并排除其他诊断后,诊断为淋巴水肿。皮肤活检显示皮肤硬化符合淋巴水肿表现。时间上的关联提示TNFα抑制剂的使用与淋巴水肿的发生之间存在联系。TNFα抑制剂被广泛用于治疗包括淋巴水肿在内的炎症性疾病。矛盾的是,有报告提示使用TNFα抑制剂后会出现银屑病、血管炎和其他炎症性皮肤疾病。本文还对相关文献进行了综述。